螺旋管内高压汽水两相流动沸腾干涸点的研究

在较宽的实验参数范围内(系统压力P=8～15 MPa,质量流速G=800～1800 kg·m~(-2)·s~(-1),壁面热流密度q_w=200～950 kW·m~(-2))对一立式螺旋管内(管内径为10 mm,螺旋直径为300 mm,节距为50 mm)汽水两相流动沸腾干涸特性进行了实验研究。通过研究,获得了干涸发生时螺旋管圈壁温的分布特征以及压力、质量流速和壁面热流密度这三个参数对临界干度的影响规律。同时在实验数据的基础上,提出了一个适用于计算螺旋管内高压高含汽率工况下汽水两相流临界干度的经验关系式。     

腔内倍频调Q激光器中脉冲光场的时间不稳定性研究

以腔内倍频调Q激光器工作原理为基础,研究了多种形式抽运光分布的情况下倍频光的脉冲形状以及脉冲持续过程中光场分布的时间不稳定性,分析了倍频光光束质量随时间的变化规律.发现腔内倍频调Q激光器输出的倍频光光场分布在脉冲的持续过程中并不稳定,呈持续变化.对高斯型抽运的情况研究发现,减小腔长会使脉冲光场分布的不稳定性减小;而增加...     

大口径薄片激光器中的谐振模式及光束质量诊断

基于自再现原理,利用菲涅耳-基尔霍夫衍射积分方程,引入腔镜失调、激光介质上的增益分布以及光阑口径,采用本征矢量法分析了大口径平凹腔薄片激光器的本征模式,并计算了相应的光束质量因子M2.建立了千瓦级薄片激光系统和光纤扫描光斑诊断装置,开展了高功率激光输出特性研究.结果表明,在大口径高功率平凹腔中多个本征模式可同时起振,获...     

耦合微盘及带输出波导的单微盘腔的耦合模式特性

光学微腔具有很高的品质因子和很小的模式体积,在光电子器件研究方面具有重要的应用价值.运用时域有限差分(FDTD)法和Padé近似频谱分析法模拟研究了耦合微盘及带输出波导的单微盘微腔由于空间对称性破坏导致的模式耦合现象;特别计算了耦合模式的场分布和品质因子,并由场分布得出不同角量子数模式的能量比例.对耦合微盘,模式耦合引...     

双曲余弦高斯列阵光束在湍流大气中的光束传输因子

本文推导出了双曲余弦高斯(ChG)列阵光束在湍流大气中的光束传输因子( M ^{2因子)的解析公式,并采用相对 M 2因子研究了湍流对 M 2因子的影响.研究表明,在湍流大气中 M 2因子不再是一个传输不变量,湍流使得 M 2因子增大.非相干合成情况下, M 2因子随着传输距离、光束参数、相对子光束间距和子光束数目的增大而增大.相干合成情况下, M 2因子随光束参数和相对子光束间距的增大呈现振荡上升.相干合成情况下的 M 2因子比 关键词： M2因子)')" href="#">光束传输因子(M2因子) 光束质量 双曲余弦高斯列阵光束 大气湍流}     

XMgO·YMg(OH)_2吸附剂除氟机理及其净化水的水质研究

研究了XMg O·YMg(OH)2对水中氟离子的吸附性能,考察了吸附时间、吸附剂用量、含氟水p H值、温度、含氟水初始浓度等因素对吸附的影响。实验结果表明,在较宽的p H(3.4~8.4)值和水温(22~51℃)范围内,XMg O·YMg(OH)2对水中氟离子具有极强的吸附能力,室温下0.4g XMg O·YMg(OH)2可将100m L浓度为30mg F-1·L-1含氟水处理为符合含氟标准的饮用水。氟离子在XMg O·YMg(OH)2上的吸附速率较大,30min内基本达到吸附平衡,吸附平衡符合Langmuir方程,在50min内达到饱和吸附,室温下饱和吸附量为13.46mg·g-1。净化水呈微碱性,含有5.68~15.07mg·L-1Mg2+,有益于人体健康。吸附饱和后的XMg O·YMg(OH)2经焙烧再生,除氟率可达81%。     

An innovative method for quality control of conjugated Haemophilus influenzae vaccines: A short review of two-dimensional nanoparticle electrophoresis

This article provides an overview of a 2D agarose electrophoretic procedure for the characterization of semi-synthetic Haemophilus influenzae type b meningitis vaccines that were prepared for the immunization of small children. The analysis of such vaccines has been particularly challenging because the vaccine particles (i) are highly negatively charged, (ii) are as large as or even larger than intact viruses, and (iii) have a continuous (polydisperse) size distribution because of randomizing steps in the vaccine production (sonification and crosslinking). As a result of these characteristics, 1D electrophoresis of the vaccines produced smears without discernable peaks, but with a second dimension of separation a characteristic vaccine fingerprint was obtained. Whereas O’Farrell gels can accomplish a 2D separation according to size and charge for samples with protein-sized particles, nondenaturing 2D agarose electrophoresis achieves a similar result for much larger virus-sized particles. The separation principle, however, is different. Even though the 2D electrophoretic method was developed from 1983 to 1995, it remains a promising tool for vaccine quality control and for predicting vaccine effectiveness. Modern technology makes the analysis significantly more practical and affordable than it was more than 10 years ago, and the method is applicable to a variety of conjugated vaccines and complex mixtures of virus-sized particles.     

Cardiac markers: a clear cause for point-of-care testing

Point-of-care testing (POCT) in patients with ischemic heart disease is driven by the time-critical need for fast, specific, and accurate results to initiate therapy instantly. According to current guidelines, the results of the cardiac marker testing should be available to the physician within 30 min (“vein-to-brain” time) to initiate therapy within 60–90 min (“door-to-needle” time) after the patient has arrived at the emergency room or intensive care unit. This article reviews the current efforts to meet this goal (1) by implementing POCT of established biochemical markers such as cardiac troponins, creatine kinase MB, and myoglobin, in accelerated diagnosis and management workflow schemes, (2) by improving current POCT methods to obtain more accurate, more specific, and even faster tests through the integration of optical and electrochemical sensor technology, and (3) by identifying new markers for the very early and sensitive detection of myocardial ischemia and necrosis. Furthermore, the specific requirements for cardiac POCT in regard to analytical performance, comparability, and diagnostic sensitivity/specificity are discussed. For the future, the integration of new immunooptical and electrochemical chip technology might speed up diagnosis even further. However, every new development will have to meet the stringent method validation criteria set for corresponding central laboratory testing.     

Multivariate Bayesian process control for a finite production run

Most industrial products and processes are characterized by several, typically correlated measurable variables, which jointly describe the product or process quality. Various control charts such as Hotelling’s T², EWMA and CUSUM charts have been developed for multivariate quality control, where the values of the chart parameters, namely the sample size, sampling interval and the control limits are determined to satisfy given economic and/or statistical requirements. It is well known that this traditional non-Bayesian approach to a control chart design is not optimal, but very few results regarding the form of the optimal Bayesian control policy have appeared in the literature, all limited to a univariate chart design. In this paper, we consider a multivariate Bayesian process mean control problem for a finite production run under the assumption that the observations are values of independent, normally distributed vectors of random variables. The problem is formulated in the POMDP (partially observable Markov decision process) framework and the objective is to determine a control policy minimizing the total expected cost. It is proved that under standard operating and cost assumptions the control limit policy is optimal. Cost comparisons with the benchmark chi-squared chart and the MEWMA chart show that the Bayesian chart is highly cost effective, the savings are larger for smaller values of the critical Mahalanobis distance between the in-control and out-of-control process mean.     

Contract and product quality in platform selling

More and more e-tailers (platforms) are allowing manufacturers direct access to customers. Two common contracts are offered by platforms to manufacturers: the revenue sharing contract where a platform appropriates a portion of the manufacturer’s revenue, and the fixed fee contract where a platform charges a fixed rent for each sale. Using an analytical model, this paper studies the interrelationship between a platform’s contract choice and a manufacturer’s product quality decision. We find that if product quality is exogenously given, the platform will always adopt the revenue sharing contract. If the manufacturer endogenously decides the quality, however, the platform’s contract choice may be changed. This is because the revenue sharing contract, compared to fixed fee, leads to a lower selling price of the manufacturer, whereas the fixed fee contract can motivate a higher quality than does revenue sharing. As a result, a large (small) market heterogeneity induces the platform to adopt the revenue sharing (fixed fee) contract. We also extend the model to several directions, finding that longer product line, manufacturer competition, lower marginal production cost, and higher platform cost all tend to induce the platform to put forward a fixed fee contract; while if quality decision is less flexible than contract decision, the platform is more ready to embrace revenue sharing. Besides, when there are two platforms competing for the same market, they should differentiate their contract choices so as to mitigate competition.